TIANJIN, China, Aug. 17, 2021 /PRNewswire/ -- SINOMED, a leading international medical device company, announced the first commercial implantation of the HT Supreme® Drug-Eluting Stent (DES) at University Hospital Galway in partnership with the National University of Ireland Galway (NUI Galway), marking the start of the European launch. The procedure was successfully performed by Professor Faisal Sharif, Professor of Translational Cardiovascular Medicine and Innovation at NUI Galway and Consultant Interventional Cardiologist at Galway University Hospitals.
Sinomed, a leading international medical device company, announced that they have teamed up with the National University of Ireland Galway (NUI Galway) to conduct a clinical trial for a new assessment method for stenting. The trial will employ the newly patented, HT Supreme Healing-Targeted Drug-Eluting Stent (DES), which has the potential to break new ground in the treatment of patients with heart disease.